

Docking & drug discovery

Máster bioinformática Universidad de Valencia
29 - Abril - 2013

Summary

- Introduction
- Small molecules **binding site** prediction
 - de-novo.
 - comparative.
- **Docking.**
 - What is docking?
 - Autodock and state-of-the-art methods.
 - An application in drug discovery : ISENTRESS.

Objective

TO LEARN **HOW-TO** USE AutoDock
Vina FOR DOCKING SMALL
MOLECULES IN THE SURFACE OF A
PROTEIN

Nomenclature

Ligand: Structure (usually a small molecule) that binds to the binding site.

Receptor: Structure (usually a protein) that contains the active binding site.


Binding site: Set of amino-acids (residues) that physically interact with the ligand (usually within 6 Ångstroms).

From sequence to function...


Sequence

MTSITPVTLANCEDEP
IHVPGAIQPHGALVTL
RADGMVLAASENIQAL
LGFVASPGSYLTQEQV
GPEVLRMLEEGLTGNG
P

Structure



Function





- conserved +



Program

Binding site prediction

AutoDock










binding site prediction



- Sometimes, we know the binding site for a ligand because it has been **co-crystallized** with the protein.
- **Localize** the binding site/s for a given molecule.
- There could be **several** binding sites in a protein surface.
- Two different approaches for binding site prediction : **de novo & comparative prediction**.

Scoring

NAD



$$\tilde{f} = (f - \langle f \rangle) / \sigma_f.$$

Getting the z-score for each feature.

$$\rightarrow w_k = \frac{1}{M} \sum_{\alpha=1}^M \tilde{f}_k^{(\alpha)}$$

M = number of proteins in training set


$$F(P) = \sum_{k=1}^7 w_k \cdot \tilde{f}_k(P),$$

Optimization, maximizing score.

Ligand fingerprints


	Compactness	Conservation	Charge density	B-factor	Protrusion coefficient	Convexity score	Hydrophobicity
ADP	-1.266	-2.009	0.447	-0.414	-1.521	-1.388	-0.118
AMP	-1.62	-1.962	0.341	-0.381	-1.909	-1.944	-0.518
ANP	-1.007	-2.227	0.176	-0.392	-1.706	-1.595	-0.14
ATP	-1.122	-2.156	0.228	-0.274	-1.845	-1.768	0.038
BOG	-2.067	-0.012	0.552	-0.465	-0.356	-0.49	-0.781
CIT	-2.948	-1.58	0.563	-0.527	-0.922	-0.838	-0.113
FAD	0.505	-2.108	0.366	-0.702	-1.735	-1.725	-0.75
FMN	-1.132	-1.98	0.382	-0.387	-1.803	-1.886	-0.695
FUC	-3.43	0.016	-0.295	-0.123	0.002	0.132	0.459
GAL	-3.186	-0.538	-0.234	-0.068	-0.906	-0.987	0.298
GDP	-1.061	-1.471	0.409	-0.81	-1.472	-1.423	0.182
GLC	-2.813	-1.247	-0.207	-0.399	-1.247	-1.337	-0.089
HEC	-0.172	-0.912	0.286	-0.325	-1.153	-1.27	-1.282
HEM	-0.651	-1.571	0.683	-0.51	-1.797	-1.937	-1.47
MAN	-3.72	0.131	0.105	-0.52	-0.605	-0.509	0.405
MES	-3.049	-0.24	-0.338	-0.479	-0.714	-0.926	0.296
NAD	-0.005	-1.852	0.156	-0.232	-1.775	-1.804	-0.858
NAG	-3.419	-0.46	-0.126	-0.154	-0.341	-0.523	-0.078
NAP	-0.009	-1.898	0.612	-0.321	-1.587	-1.656	-0.336
NDP	0.217	-1.741	0.535	-0.312	-1.463	-1.562	-0.498

Ligand fingerprints



Prediction accuracy

■ Random ■ Minimized



Protein function from structure

Comparative annotation. AnnoLite and AnnoLyze.

Marti-Renom et al. The AnnoLite and AnnoLyze programs for comparative annotation of protein structures.
BMC Bioinformatics (2007) vol. 8 (Suppl 4) pp. S4

BMC Bioinformatics



Proceedings

Open Access

The AnnoLite and AnnoLyze programs for comparative annotation of protein structures

Marc A Marti-Renom*¹, Andrea Rossi², Fátima Al-Shahrour³, Fred P Davis², Ursula Pieper², Joaquín Dopazo³ and Andrej Sali²

Address: ¹Structural Genomics Unit, Bioinformatics Department, Centro de Investigación Príncipe Felipe (CIPF), Valencia, Spain, ²Departments of Biopharmaceutical Sciences and Pharmaceutical Chemistry, and California Institute for Quantitative Biomedical Research, University of California at San Francisco, San Francisco, CA 94143, USA and ³Functional Genomics Unit, Bioinformatics Department, Centro de Investigación Príncipe Felipe (CIPF), Valencia, Spain

Email: Marc A Marti-Renom* - mmarti@cipf.es; Andrea Rossi - andrea@salilab.org; Fátima Al-Shahrour - falshahrour@cipf.es; Fred P Davis - fred@salilab.org; Ursula Pieper - Ursula@salilab.org; Joaquín Dopazo - jdopazo@cipf.es; Andrej Sali - sali@salilab.org
* Corresponding author

from The Second Automated Function Prediction Meeting
La Jolla, CA, USA. 30 August – 1 September 2006

Published: 22 May 2007

BMC Bioinformatics 2007, 8(Suppl 4):S4 doi:10.1186/1471-2105-8-S4-S4

This article is available from: <http://www.biomedcentral.com/1471-2105/8/S4/S4>

© 2007 Marti-Renom et al; licensee BioMed Central Ltd.

This is an open access article distributed under the terms of the Creative Commons Attribution License (<http://creativecommons.org/licenses/by/2.0>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Background: Advances in structural biology, including structural genomics, have resulted in a rapid increase in the number of experimentally determined protein structures. However, about half of the structures deposited by the structural genomics consortia have little or no information about their biological function. Therefore, there is a need for tools for automatically and comprehensively annotating the function of protein structures. We aim to provide such tools by applying comparative protein structure annotation that relies on detectable relationships between protein structures to transfer functional annotations. Here we introduce two programs, AnnoLite and AnnoLyze, which use the structural alignments deposited in the DBAli database.


Description: AnnoLite predicts the SCOP, CATH, EC, InterPro, PfamA, and GO terms with an average sensitivity of ~90% and average precision of ~80%. AnnoLyze predicts ligand binding site and domain interaction patches with an average sensitivity of ~70% and average precision of ~30%, correctly localizing binding sites for small molecules in ~95% of its predictions.

Conclusion: The AnnoLite and AnnoLyze programs for comparative annotation of protein structures can reliably and automatically annotate new protein structures. The programs are fully accessible via the Internet as part of the DBAli suite of tools at <http://salilab.org/DBAli/>.

Background

Genomic efforts are providing us with complete genetic blueprints for hundreds of organisms, including humans.

We are now faced with assigning, understanding and modifying the functions of proteins encoded by these genomes. This task is generally facilitated by protein 3D



Page 1 of 12

(page number not for citation purposes)


(This article contains supplementary material, which is available to authorized users.)

15
14
13
12
11
10
9
8
7
6
5
4
3
2
1

bioRxiv preprint doi: <https://doi.org/10.1101/111111>; this version posted April 29, 2013. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-NC-ND 4.0 International license.

DBAli_{v2.0} database

<http://www.dbali.org>




AnnoLyze

Inherited ligands: 4

Ligand	Av. binding site seq. id.	Av. residue conservation	Residues in predicted binding site (size proportional to the local conservation)
MO2	59.03	0.185	48 49 52 62 63 66 67 113 116
CRY	20.00	0.111	23 29 31 37 44 48 49 83 85 94 96 103 121
BOG	20.00	0.111	19 20 21 48 49 51 96 98 136
ACY	15.87	0.163	23 29 31 37 44 45 81 83 85 94 96 98 103 121 135

Inherited partners: 1

Partner	Av. binding site seq. id.	Av. residue conservation	Residues in predicted binding site (size proportional to the local conservation)
d.113.1.1	23.68	0.948	19 20 50 51 52 53 54 55 56 57 58 77 78 79 80 81 82 83 84 85 93 95 97 99 134 135 138 142 145



Benchmark

	Number of chains
Initial set*	78,167
LigBase**	30,126
Non-redundant set***	4,948 (8,846 ligands)

**all PDB chains larger than 30 aminoacids in length (8th of August, 2006)*

***annotated with at least one ligand in the LigBase database*

****not two chains can be structurally aligned within 3Å, superimposing more than 75% of their Ca atoms, result in a sequence alignment with more than 30% identity, and have a length difference inferior to 50aa*


	Number of chains
Initial set*	78,167
πBase**	30,425
Non-redundant set***	4,613 (11,641 partnerships)

**all PDB chains larger than 30 aminoacids in length (8th of August, 2006)*

***annotated with at least one partner in the π Base database*


****not two chains can be structurally aligned within 3Å, superimposing more than 75% of their Ca atoms, result in a sequence alignment with more than 30% identity, and have a length difference inferior to 50aa*

Method




Inherited ligands: 4

Ligand	Av. binding site seq. id.	Av. residue conservation	Residues in predicted binding site (size proportional to the local conservation)
MO2	59.03	0.185	48 49 52 62 63 66 67 113 116
CRY	20.00	0.111	23 29 31 37 44 48 49 83 85 94 96 103 121
BOG	20.00	0.111	19 20 21 48 49 51 96 98 136
ACY	15.87	0.163	23 29 31 37 44 45 81 83 85 94 96 98 103 121 135



Inherited partners: 1



Partner	Av. binding site seq. id.	Av. residue conservation	Residues in predicted binding site (size proportional to the local conservation)
d.113.1.1	23.68	0.948	19 20 50 51 52 53 54 55 56 57 58 77 78 79 80 81 82 83 84 85 93 95 97 99 134 135 138 142 145



Scoring function

Ligands

Partners



Aloy *et al.* (2003) J.Mol.Biol. 332(5):989-98.

Sensitivity .vs. Precision

	Optimal cut-off	Sensitivity (%) Recall or TPR	Precision (%)
Ligands	30%	71.9	13.7
Partners	40%	72.9	55.7

$$\text{Sensitivity} = \frac{TP}{TP + FN} \quad \text{Precision} = \frac{TP}{TP + FP}$$



However, 90-95% of aa correctly predicted

Example (2azwA)

Structural Genomics Unknown Function

Inherited ligands: 4			
Ligand	Av. binding site seq. id.	Av. residue conservation	Residues in predicted binding site (size proportional to the local conservation)
MO2	59.03	0.185	48 49 52 62 63 66 67 113 116
CRY	20.00	0.111	23 29 31 37 44 48 49 83 85 94 96 103 121
BOG	20.00	0.111	19 20 21 48 49 51 96 98 136
ACY	15.87	0.163	23 29 31 37 44 45 81 83 85 94 96 98 103 121 135


Inherited partners: 1			
Partner	Av. binding site seq. id.	Av. residue conservation	Residues in predicted binding site (size proportional to the local conservation)
d.113.1.1	23.68	0.948	19 20 50 51 52 53 54 55 56 57 58 77 78 79 80 81 82 83 84 85 93 95 97 99 134 135 138 142 145



Other binding-site prediction web methods


- **Metapocket 2.0** (<http://projects.biotec.tu-dresden.de/metapocket/>).
 - ★ Metapredictor : LIGSITE,PASS, Q-SiteFinder, SURNET, Fpocket,GECOM, ConCavity, POCASA.
- **LISE** (<http://lise.ibms.sinica.edu.tw>).
 - ★ Binding Site-Enriched Protein Triangles method. Published in April 2012.

Docking of small molecules. Autodock Vina



DISCLAIMER!

Credit should go to Dr. Oleg Trott, Dr. Ruth Huey and Dr. Garret M. Morris



Using AutoDock 4 with ADT: A Tutorial

*Dr. Ruth Huey
&
Dr. Garrett M. Morris*

<http://autodock.scripps.edu>

<http://vina.scripps.edu>

Software News and Update AutoDock Vina: Improving the Speed and Accuracy of Docking with a New Scoring Function, Efficient Optimization, and Multithreading

OLEG TROTT, ARTHUR J. OLSON
Department of Molecular Biology, The Scripps Research Institute, La Jolla, California

Received 3 March 2009; Accepted 21 April 2009

DOI 10.1002/jcc.21334

Published online in Wiley InterScience (www.interscience.wiley.com).

Abstract: AutoDock Vina, a new program for molecular docking and virtual screening, is presented. AutoDock Vina achieves an approximately two orders of magnitude speed-up compared with the molecular docking software previously developed in our lab (AutoDock 4), while also significantly improving the accuracy of the binding mode predictions, judging by our tests on the training set used in AutoDock 4 development. Further speed-up is achieved from parallelism, by using multithreading on multicore machines. AutoDock Vina automatically calculates the grid maps and clusters the results in a way transparent to the user.

© 2009 Wiley Periodicals, Inc. *J Comput Chem* 00: 000–000, 2009

Key words: AutoDock; molecular docking; virtual screening; computer-aided drug design; multithreading; scoring function

Introduction

Molecular docking is a computational procedure that attempts to predict noncovalent binding of macromolecules or, more frequently, of a macromolecule (receptor) and a small molecule (ligand) efficiently, starting with their unbound structures, structures obtained from MD simulations, or homology modeling, etc. The goal is to predict the bound conformations and the binding affinity.

The prediction of binding of small molecules to proteins is of particular practical importance because it is used to screen virtual libraries of drug-like molecules to obtain leads for further drug development. Docking can also be used to try to predict the bound conformation of known binders, when the experimental holo structures are unavailable.¹

One is interested in maximizing the accuracy of these predictions while minimizing the computer time they take, because the computational resources spent on docking are considerable. For example, hundreds of thousands of computers are used for running docking in FightAIDS@Home and similar projects.²

Theory

In the spectrum of computational approaches to modeling receptor–ligand binding,

- molecular dynamics with explicit solvent,
- molecular dynamics and molecular mechanics with implicit solvent, and
- molecular docking

can be seen as making an increasing trade-off of the representational detail for computational speed.³

Among the assumptions made by these approaches is the commitment to a particular protonation state of and charge distribution in the molecules that do not change between, for example, their bound and unbound states. Additionally, docking generally assumes much or all of the receptor rigid, the covalent lengths, and angles constant, while considering a chosen set of covalent bonds freely rotatable (referred to as active rotatable bonds here).

Importantly, although molecular dynamics directly deals with energies (referred to as force fields in chemistry), docking is ultimately interested in reproducing chemical potentials, which determine the bound conformation preference and the free energy of binding. It is a qualitatively different concept governed not only by the minima in the energy profile but also by the shape of the profile and the temperature.^{4,5}

Docking programs generally use a scoring function, which can be seen as an attempt to approximate the standard chemical potentials of the system. When the superficially physics-based terms like the 6–12 van der Waals interactions and Coulomb energies are used in the scoring function, they need to be significantly empirically weighted, in part, to account for this difference between energies and free energies.^{4,5}

Correspondence to: A.J. Olson; e-mail: olson@scripps.edu

Contract/grant sponsor: NIH; contract/grant number: 2R01GM069832


© 2009 Wiley Periodicals, Inc.

O. Trott, A. J. Olson, *Journal of Computational Chemistry* (2009)

What is docking?

Predicting the best ways two molecules interact.


- ◆ Obtain the 3D structures of the two molecules.
- ◆ Locate the best binding site (**Remember AnnoLyze, Metapocket...**)
- ◆ Here, small molecule docking in protein.
- ◆ **Determine the best binding mode. (POSE) .**



What is docking?

Predicting the **best** ways two molecules interact.

- ◆ We need to quantify or rank solutions
- ◆ We need a good scoring function for such ranking
- ◆ Can we determine the best solution?




Scoring!

What is docking?

Predicting the best **ways** two molecules interact.

- ◆ X-ray and NMR structures are just ONE of the possible solutions
- ◆ There is a need for a search solution.
- ◆ Can we get all possible solutions?




Sampling!

**As everything in
BIOINFORMATICS...**

**REPRESENTATION
SCORING
SAMPLING**

REPRESENTATION




SCORING

AutoDock Vina

$$\Delta G_{binding} = \Delta G_{vdW} + \Delta G_{elec} + \Delta G_{hbond} + \Delta G_{desolv} + \Delta G_{tors}$$


- ΔG_{vdW}
12-6 Lennard-Jones potential




- ΔG_{elec}
Coulombic with Solmajer-dielectric

$$\epsilon(r) = A + \frac{B}{1 + ke^{-\lambda Br}}$$


- ΔG_{hbond}
12-10 Potential with Goodford Directionality



- ΔG_{desolv}
Stouten Pairwise Atomic Solvation Parameters




- ΔG_{tors}
Number of rotatable bonds



<http://autodock.scripps.edu/resources/science/equations>

PROBLEM!

Very CPU time consuming...



Dihydrofolate reductase with a metotrexate (4dfr.pdb)

$$N = T^{360/i}$$

N: number of conformations

T: number of rotatable bonds

i: incremental degrees

Metotrexato


10 rotatable bonds

30° increments (discrete)

10¹² plausible conformations!

SOLUTION

Use of grid maps!




- ◆ Saves lots of time (compared to classical MM/MD).
- ◆ Need to map each atom to a grid point.
- ◆ Limits the search space!. From continue to discrete space.

AutoGrid Vina + ADT Tools

Use of grid maps!


- ◆ Center of grid *
 - ◆ center of a bind ligand.
 - ◆ center of receptor.
 - ◆ a selected atom or coordinate.
 - ◆ **Binding Site Center of Mass (CoM) .**
- ◆ Box dimension *
 - ◆ At least, **two** times the size of the ligand.
 - ◆ 3-Dimensions X,Y, Z.
- ◆ Grid resolution (spacing)
 - ◆ default **0.375 Angstroms.**
- ◆ Number of grid points (dimension)
 - ◆ use **ONLY** even numbers



With VINA + ADT Tools much simplified (*)

Vina + AutoDock Tools

Good that we have AutoDock Tools (ATD)




<http://autodock.scripps.edu/resources/adt>

AutoDock Tools


Very useful and easy to use!

- ◆ Is the free GUI for AutoDock.
- ◆ We can use it for setting up grid size and grid position.
- ◆ We can also prepare the input molecules :
 - ◆ Adding all hydrogens or only polar hydrogens.
 - ◆ Assigning polar charges to the ligand and the receptor.
 - ◆ Set up rotatable bonds in the ligand using a graphical version of AutoTors.
 - ◆ Select the flexible side chains in flexible docking.
- ◆ Useful for analyzing the results, after vina docking.



Search algorithms

Simulated Annealing




Search algorithms

Genetic Algorithm


Use of a Genetic Algorithm as a sampling method

- Each conformation is described as a set of rotational angles.
- 64 possible angles are allowed to each of the bond in the ligand.
- Each plausible dihedral angle is codified in a set of binary bits ($2^6=64$)
- Each conformation is codified by a so called chromosome with 4×6 bits (0 or 1)

111010.010110.001011.010010






$$\Phi_1 = 1 \times 2^5 + 1 \times 2^4 + 1 \times 2^3 + 0 \times 2^2 + 1 \times 2^1 + 0 \times 2^0 = 58^\circ$$



Search algorithms

Genetic Algorithm

Population (*ie*, set of chromosomes or configurations)



011010.010110.011010.010111
111010.010110.001011.010010
001010.010101.000101.010001
101001.101110.101010.001000
001010.101000.011101.001011



← Chromosome

↑ Gene

Search algorithms

Genetic Algorithm

Genetic operators...



011010.010110.011010.010111





Single
mutation

011010.01**1**110.011**1**10.010111

Search algorithms

Genetic Algorithm

Genetic operators...



001010.010101.000101.010001

011010.010110.011010.010111

Recombination

001010.010101.011010.010111

011010.010110.000101.010001

Search algorithms

Genetic Algorithm

Genetic operators...

011010.010110.011010.010111
111010.010110.001011.010010
001010.010101.000101.010001
101001.101110.101010.001000
001010.101000.011101.001011

Migration




111110.010010.011110.010101
101010.110110.011011.011010
001010.010101.000101.010001
101101.101010.101011.001100
011010.100000.011001.101011

Vina docking results

Goodsell, D. S. and Olson, A. J. (1990), Automated Docking of Substrates to Proteins by Simulated Annealing Proteins:Structure, Function and Genetics., 8: 195-202.
Morris, G. M., et al. (1996), Distributed automated docking of flexible ligands to proteins: Parallel applications of AutoDock 2.4 J. Computer-Aided Molecular Design, 10: 293-304.
Morris, G. M., et al. (1998), Automated Docking Using a Lamarckian Genetic Algorithm and an Empirical Binding Free Energy Function J. Computational Chemistry, 19: 1639-1662.
Huey, R., et al. (2007), A Semiempirical Free Energy Force Field with Charge-Based Desolvation J. Computational Chemistry, 28: 1145-1152.

Vina docking results



Goodsell, D. S. and Olson, A. J. (1990), Automated Docking of Substrates to Proteins by Simulated Annealing Proteins:Structure, Function and Genetics., 8: 195-202.
Morris, G. M., et al. (1996), Distributed automated docking of flexible ligands to proteins: Parallel applications of AutoDock 2.4 J. Computer-Aided Molecular Design, 10: 293-304.
Morris, G. M., et al. (1998), Automated Docking Using a Lamarckian Genetic Algorithm and an Empirical Binding Free Energy Function J. Computational Chemistry, 19: 1639-1662.
Huey, R., et al. (2007), A Semiempirical Free Energy Force Field with Charge-Based Desolvation J. Computational Chemistry, 28: 1145-1152.

Vina docking results

One practical case...


Vina output log

HCBR + Rimonabant

```
# If you used AutoDock Vina in your work, please cite: #
# #
# O. Trott, A. J. Olson, #
# AutoDock Vina: improving the speed and accuracy of docking #
# with a new scoring function, efficient optimization and #
# multithreading, Journal of Computational Chemistry 31 (2010) #
# 455-461 #
# #
# DOI 10.1002/jcc.21334 #
# #
# Please see http://vina.scripps.edu for more information. #
#####
WARNING: The search space volume > 27000 Angstrom^3 (See FAQ)
Detected 4 CPUs
Reading input ... done.
Setting up the scoring function ... done.
Analyzing the binding site ... done.
Using random seed: 682849564
Performing search ... done.
Refining results ... done.


mode | affinity | dist from best mode
      | (kcal/mol) | rmsd l.b. | rmsd u.b.
-----+-----+-----+-----
1 | -11.3 | 0.000 | 0.000
2 | -10.4 | 1.077 | 2.294
3 | -10.2 | 1.327 | 2.006
4 | -10.0 | 2.334 | 4.484
5 | -9.9 | 14.488 | 16.499
6 | -9.9 | 1.542 | 3.005
7 | -9.8 | 36.046 | 37.733
8 | -9.8 | 36.084 | 37.975
9 | -9.8 | 32.479 | 34.497

Writing output ... done.
fran@davide-desktop:~/Documents/TestProject/autodock_vina_1_1_2_linux
```



AutoDock Vina

Where to get help...



The screenshot shows a web browser window with the title "AutoDock Vina - molecular docking and virtual screening program". The address bar shows "http://vina.scripps.edu/". The website has a blue navigation bar with links for "Home", "Download", "Tutorial", "Manual", and "Forum". The main content area features four panels (a, b, c, d) showing molecular docking results. Panel (a) shows a ligand (green) docked into a protein binding site (yellow and cyan). Panel (b) shows a ligand (green) docked into a protein binding site (yellow). Panel (c) shows a ligand (green) docked into a protein binding site (yellow and cyan). Panel (d) shows a ligand (green) docked into a protein binding site (yellow). To the right of the panels is a section titled "AutoDock Vina" with a description: "AutoDock Vina is a new program for drug discovery, [molecular docking](#) and virtual screening, offering multi-core capability, high performance and enhanced accuracy and ease of use. [\[1\]](#)". Below this is another paragraph: "AutoDock Vina has been designed and implemented by [Dr. Oleg Trott](#) in the Molecular Graphics Lab at The Scripps Research Institute." Below that is a third paragraph: "The image on the left illustrates the results of flexible docking (green) superimposed on the crystal structures of (a) indinavir, (b) atorvastatin, (c) imatinib, and (d) oseltamivir." At the bottom of the page, the URL "http://vina.scripps.edu" is displayed in blue text.

Vina 1.1.1

Alternatives

Progressive building

Conformational search

Binding site description

Genetic algorithms

Virtual screening

Molecular dynamics

Databases

MIMUMBA
COBRA
WIZRAD

GRID

GOLD
Others

AutoDOCK

CAVEAT
FOUNDATION
CLIX
NEWLEAD
LEAPFROG


FLEXX
DOCK
GROW
GroupBUILD
LUDI
LEGEND
SPROUT
BUILDER
GENSTAR

MCSS
CONCEPTS

AutoDock 4.0


Why AutoDock over others

Sousa, S.F., Fernandes, P.A. & Ramos, M.J. (2006)
**Protein-Ligand Docking: Current Status
and Future Challenges** *Proteins*, **65**:15-26



AutoDock 4.0


Why AutoDock over others




Vina vs. Autodock 4

Important improvements...

More accurate



4-fold faster



O. Trott, A. J. Olson, AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization and multithreading, Journal of Computational Chemistry 31 (2010) 455-461

Improvements of Vina

Recently published...

Handoko, S. D., Xuchang Ouyang, Chinh Tran To Su, Chee Keong Kwoh & Yew Soon Ong. *IEEE/ACM Trans. Comput. Biol. and Bioinf.* **9**, 1266–1272

1266 IEEE/ACM TRANSACTIONS ON COMPUTATIONAL BIOLOGY AND BIOINFORMATICS, VOL. 9, NO. 5, SEPTEMBER/OCTOBER 2012

QuickVina: Accelerating AutoDock Vina Using Gradient-Based Heuristics for Global Optimization

Stephanus Daniel Handoko, Xuchang Ouyang, Chinh Tran To Su, Chee Keong Kwoh, and Yew Soon Ong

Abstract—Predicting binding between macromolecule and small molecule is a crucial phase in the field of rational drug design. AutoDock Vina, one of the most widely used docking software released in 2009, uses an empirical scoring function to evaluate the binding affinity between the molecules and employs the iterated local search global optimizer for global optimization, achieving a significantly improved speed and better accuracy of the binding mode prediction compared its predecessor, AutoDock 4. In this paper, we propose further improvement in the local search algorithm of Vina by heuristically preventing some intermediate points from undergoing local search. Our improved version of Vina—dubbed QVina—achieved a maximum acceleration of about 25 times with the average speed-up of 8.34 times compared to the original Vina when tested on a set of 231 protein-ligand complexes while maintaining the optimal scores mostly identical. Using our heuristics, larger number of different ligands can be quickly screened against a given receptor within the same time frame.

Index Terms—Artificial intelligence, bioinformatics, global optimization, gradient methods.

1 BACKGROUND

MOLECULAR docking is a computational process trying to find the binding between a macromolecule (the receptor) and a small molecule (the ligand). Since it can be used in predicting binding conformations and affinities between drug molecules and their target proteins, leading to the understanding of the biological mechanism behind those bindings, molecular docking is with great value to drug design [1].

Generally, docking is an optimization problem that attempts to find the binding conformation with global lowest energy, the landscape of which is approximated by a scoring function. The introduction of flexibility in the ligand, or further in the receptor as well, will make the problem more sophisticated [1], [2]. The major issue of the difficulty comes from the large number of degrees of freedom in modeling the molecular system. Since 1980s, various programs and software have been developed in order to perform molecular binding, such as DOCK [1], AutoDock [3], GOLD [4], ICM [5], and FlexX [6] and different scoring functions have been

proposed. However, after decades of development, docking is still a time-consuming task even with the most powerful computing resources to-date. In 2009, AutoDock Vina [7] (referred to as Vina afterward) was released by the same group who invented the earlier versions of AutoDock, which is one of the most popular docking software. Vina uses an empirical scoring function to evaluate the binding affinity between the molecules, and the iterated local search global optimizer for global optimization. This combination is reported to be successful to achieve approximately two orders of magnitude improvement in speed, and simultaneously, a significantly better accuracy of the binding mode prediction compared to AutoDock 4 [7].

In this paper, we proposed an improvement in the local search procedure of Vina. By heuristically preventing some of the intermediate points from performing local search, our improved version of Vina, named QuickVina (QVina), achieved a maximum speed-up of about 25 times with an average speed-up of 8.34 over a testing data set of 231 protein-ligand complexes from the PDBBind [8] and a tendency to have a higher speed-up with the larger number of degrees of freedom, without compromising the quality of docking result.

2 METHODS

2.1 Analyzing the Global Optimization Algorithm in Vina

At the time this paper is drafted, the source code of the AutoDock Vina is available free of charge at its website: <http://vina.scripps.edu/>. With the lack of detailed explanation on how exactly the search algorithm works in Vina, we performed a thorough analysis of the source code. In Fig. 1, we present the pseudocode of the global optimization approach employed by Vina. Fundamentally, it is a form of

- S.D. Handoko is with the Centre for Computational Intelligence, School of Computer Engineering, Nanyang Technological University, Blk N4, #B1a-02, Nanyang Avenue, Singapore 639798. E-mail: sdhandoko@ntu.edu.sg.
- X. Ouyang and C.T.T. Su are with the Bioinformatics Research Centre, School of Computer Engineering, Nanyang Technological University, Blk NS4, #04-33, Nanyang Avenue, Singapore 639798. E-mail: {xouyang1, sutr0003}@e.ntu.edu.sg.
- C.K. Kwoh and Y.S. Ong are with the School of Computer Engineering, Nanyang Technological University, Blk N4, #02a-26, Nanyang Avenue, Singapore 639798. E-mail: {asckkwoh, asyong}@ntu.edu.sg.

Manuscript received 8 Nov. 2011; revised 11 Mar. 2012; accepted 20 Apr. 2012; published online 23 May 2012.
For information on obtaining reprints of this article, please send e-mail to: tcbb@computer.org, and reference IEEECS Log Number TCBB-2011-11-0290.

Digital Object Identifier no. 10.1109/TCBB.2012.82.

1545-5963/12/\$31.00 © 2012 IEEE

Published by the IEEE CS, CI, and EMB Societies & the ACM

AutoDock Example

Discovery of a novel binding trench in HIV Integrase

Schames, J.R., R.H. Henchman, J.S. Siegel, C.A. Sotriffer, H. Ni, and J.A. McCammon, Discovery of a novel binding trench in HIV integrase. J Med Chem, 2004. 47(8): 1879-81

The screenshot shows the Merck website's newsroom page. At the top, there is a navigation bar with the Merck logo and the slogan "Where patients come first". To the right of the logo are links for "Patients & Caregivers", "Healthcare Professionals", and "Worldwide", along with a "Quick Find" search box. Below the navigation bar is a horizontal menu with links for "HOME", "ABOUT MERCK", "PRODUCTS", "NEWSROOM", "INVESTOR RELATIONS", "CAREERS", "RESEARCH", "LICENSING", and "THE MERCK MANUALS". The main content area is titled "Product News" and features a large image of a hand holding a microphone. The primary article is titled "FDA Approves ISENTRESS™ (raltegravir) Tablets, First-in-Class Oral HIV-1 Integrase Inhibitor". The article text states that the FDA granted accelerated approval for ISENTRESS in combination with other antiretroviral agents for the treatment of HIV-1 infection in treatment-experienced adult patients. It also mentions that longer-term data will be required for traditional approval. To the right of the article is a sidebar titled "ABOUT ISENTRESS" with links for "Full Prescribing Information" and "Patient Product Information". At the bottom left of the page, there are links for "Contact Newsroom", "Podcast", and "RSS".

Where patients come first **MERCK** Patients & Caregivers | Healthcare Professionals | Worldwide Quick Find Search

HOME | ABOUT MERCK | PRODUCTS | NEWSROOM | INVESTOR RELATIONS | CAREERS | RESEARCH | LICENSING | THE MERCK MANUALS

Newsroom

- Product News
- Research & Development News
- Corporate News
- Financial News
- Corporate Responsibility News
- Fact Sheet
- Executive Speeches
- Webcasts
- VIOXX® (rofecoxib) Information Center

Contact Newsroom
Podcast
RSS

Product News

FDA Approves ISENTRESS™ (raltegravir) Tablets, First-in-Class Oral HIV-1 Integrase Inhibitor


WHITEHOUSE STATION, N.J., Oct. 12, 2007 - Merck & Co., Inc., announced today that the U.S. Food and Drug Administration (FDA) granted ISENTRESS™ (raltegravir) tablets accelerated approval for use in combination with other antiretroviral agents for the treatment of HIV-1 infection in treatment-experienced adult patients who have evidence of viral replication and HIV-1 strains resistant to multiple antiretroviral agents.

This indication is based on analyses of plasma HIV-1 RNA levels up through 24 weeks in two controlled studies of ISENTRESS [pronounced i-sen-tris]. These studies were conducted in clinically advanced, three-class antiretroviral [nucleoside reverse transcriptase inhibitors (NRTIs), non-nucleoside reverse transcriptase inhibitors (NNRTIs) and protease inhibitors (PIs)] treatment-experienced adults. The use of other active agents with ISENTRESS is associated with a greater likelihood of treatment response. The safety and efficacy of ISENTRESS have not been established in treatment-naïve adult patients or pediatric patients. There are no study results demonstrating the effect of ISENTRESS on clinical progression of HIV-1 infection. Longer term data will be required before the FDA can consider traditional approval for ISENTRESS.

ISENTRESS™ data will be required before the FDA can consider traditional approval for effect of ISENTRESS on clinical progression of HIV-1 infection. Longer term benefits of pediatric patients. There are no study results demonstrating the efficacy of ISENTRESS have not been established in treatment-naïve adult associated with a greater likelihood of treatment response. The safety and experience of adults. The use of other active agents with ISENTRESS is associated with a greater likelihood of treatment response. The safety and efficacy of ISENTRESS have not been established in treatment-naïve adult patients or pediatric patients. There are no study results demonstrating the effect of ISENTRESS on clinical progression of HIV-1 infection. Longer term data will be required before the FDA can consider traditional approval for ISENTRESS.


Full Prescribing Information
Patient Product Information

ISENTRESS example





- › One structure known with 5CITEP
 - ◆ Not clear (low resolution)
 - ◆ Binding site near to DNA interacting site
 - ◆ Loop near the binding
- › Docking + Molecular Dynamics
 - ◆ AMBER snapshots
 - ◆ AutoDock flexible torsion thetetrazolering and indole ring.

ISENTRESS example




Schames, J.R., R.H. Henchman, J.S. Siegel, C.A. Sotriffer, H. Ni, and J.A. McCammon, Discovery of a novel binding trench in HIV integrase. *J Med Chem*, 2004. 47(8): 1879-81

ISENTRESS example







MD Two-trenches
MD One-trench
X-Ray



Schames, J.R., R.H. Henchman, J.S. Siegel, C.A. Sotriffer, H. Ni, and J.A. McCammon, Discovery of a novel binding trench in HIV integrase. *J Med Chem*, 2004. 47(8): 1879-81

ISENTRESS example



Schames, J.R., R.H. Henchman, J.S. Siegel, C.A. Sotriffer, H. Ni, and J.A. McCammon, Discovery of a novel binding trench in HIV integrase. *J Med Chem*, 2004. 47(8): 1879-81

ISENTRESS example

Where patients come first  **MERCK** Patients & Caregivers | Healthcare Professionals | Worldwide

Quick Find Search

[HOME](#) | [ABOUT MERCK](#) | [PRODUCTS](#) | [NEWSROOM](#) | [INVESTOR RELATIONS](#) | [CAREERS](#) | [RESEARCH](#) | [LICENSING](#) | [THE MERCK MANUALS](#)

Newsroom

- [Product News](#)
- [Research & Development News](#)
- [Corporate News](#)
- [Financial News](#)
- [Corporate Responsibility News](#)
- [Fact Sheet](#)
- [Executive Speeches](#)
- [Webcasts](#)
- [VIOXX® \(rofecoxib\) Information Center](#)

[Contact Newsroom](#)
[Podcast](#)
[RSS](#)

Product News



FDA Approves ISENTRESS™ (raltegravir) Tablets, First-in-Class Oral HIV-1 Integrase Inhibitor

WHITEHOUSE STATION, N.J., Oct. 12, 2007 - Merck & Co., Inc., announced today that the U.S. Food and Drug Administration (FDA) granted ISENTRESS™ (raltegravir) tablets accelerated approval for use in combination with other antiretroviral agents for the treatment of HIV-1 infection in treatment-experienced adult patients who have evidence of viral replication and HIV-1 strains resistant to multiple antiretroviral agents.

This indication is based on analyses of plasma HIV-1 RNA levels up through 24 weeks in two controlled studies of ISENTRESS [pronounced i-sen-tris]. These studies were conducted in clinically advanced, three-class antiretroviral [nucleoside reverse transcriptase inhibitors (NRTIs), non-nucleoside reverse transcriptase inhibitors (NNRTIs) and protease inhibitors (PIs)] treatment-experienced adults. The use of other active agents with ISENTRESS is associated with a greater likelihood of treatment response. The safety and efficacy of ISENTRESS have not been established in treatment-naïve adult patients or pediatric patients. There are no study results demonstrating the effect of ISENTRESS on clinical progression of HIV-1 infection. Longer term data will be required before the FDA can consider traditional approval for ISENTRESS.

ABOUT ISENTRESS

- [Full Prescribing Information](#)
- [Patient Product Information](#)

ISENTRESS®
data will be required before the FDA can consider traditional approval for
effect of ISENTRESS on clinical progression of HIV-1 infection. Longer term
benefits or harms of ISENTRESS. There are no study results demonstrating the

AutoDock / Vina

Practical considerations

- * What problem does AutoDock solve?
 - * *Flexible* ligands (4.0 *flexible* protein).
- * What range of problems is feasible?
 - * Depends on the search method:
 - * **LGA** > **GA** >> **SA** >> **LS**
 - * **SA** : can output trajectories, $D <$ about 8 torsions.
 - * **LGA** : $D <$ about 8-32 torsions.
- * When is AutoDock not suitable?
 - * No 3D-structures are available;
 - * Modelled structure of poor quality;
 - * Too many (32 torsions, 2048 atoms, 22 atom types);
 - * Target protein too flexible.

Vina

Things to know before using AutoDock

Ligand:

- * Add all hydrogens, compute Gasteiger charges, and merge non-polar H; also assign AutoDock 4 atom types
- * Ensure total charge corresponds to tautomeric state
- * Choose torsion tree root & rotatable bonds

Macromolecule:

- * Add all hydrogens, compute Gasteiger charges, and merge non-polar H; also assign AutoDock 4 atom types
- * Assign Stouten atomic solvation parameters
- * Optionally, create a flexible residues PDBQT in addition to the rigid PDBQT file
- * Compute AutoGrid maps

Vina

There is a nice tutorial, let's try it :)

AutoDockTools
Version 1.5.1 revision 1

Michel Sanner

(c) 1999-2008 Molecular Graphics Laboratory, The Scripps Research Institute
ALL RIGHTS RESERVED

NBCR

Loading Modules... 31%

<http://vina.scripps.edu/tutorial.html>

Hands on !

- Monday 13th May : AutoDock Vina tutorial.
- We will use (**in LINUX!**) :
 - AutoDock Tools ADT . <http://mgltools.scripps.edu/downloads>
 - AutoDock Vina. <http://vina.scripps.edu/download.html>
 - Pymol . <http://www.pymol.org/>

fmartinez@pcb.ub.es

Acknowledgements

This presentation was based on:

“Using AutoDock 4 with ADT. A tutorial”
by Dr. Ruth Huey and Dr. Garret M. Morris

Vina Tutorial
by Dr. Oleg Trott

